TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05930808
Drug: First Test Concor (Fasted)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Study: NCT05930808
Drug: First Reference Concor (Fasted)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
Study: NCT05930808
Drug: First Test Concor (Fed)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Study: NCT05930808
Drug: First Reference Concor (Fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
Study: NCT06294847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
Study: NCT05217355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into the Glabellar line
Study: NCT04658654
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill with inactive ingredients to mimic same appearance of roflumilast capsule
Study: NCT06026319
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05418777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of suspension with placebo by mouth every 12 hours for 10 days
Study: NCT04910815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
Study: NCT04715022
Drug: Ascorbic acid solution (American Regent Laboratories Inc.)
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
Study: NCT06128213
Drug: NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
Study: NCT00259571
Drug: retarded release phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g daily, given orally QTD
Study: NCT05412459
Drug: 99mTc-DARPinG3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
Study: NCT00088647
Drug: MST-997
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02844530
Drug: chemotherapy/ immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04748536
Drug: IRL201104
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilised powder for reconstitution for IV dosing
Study: NCT04748536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for IRL201104
Study: NCT05834868
Drug: THDB0206 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.
Study: NCT04594733
Drug: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Study: NCT04594733
Drug: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Study: NCT04680637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a subcutaneous (SC) injection.
Study: NCT05653973
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Study: NCT01561092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05666687
Drug: MIJ821
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIJ821 will be administered as an i.v. infusion
Study: NCT06110065
Drug: Percutaneous image-guided cryoneurolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
Study: NCT05344989
Drug: APNmAb005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT05344989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT04778514
Drug: Dual Prevention Pill
Normalized name: Gas-X Prevention Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single over-encapsulated DPP containing a PrEP tablet and a COC
Study: NCT04778514
Drug: PrEP and combined oral contraceptive (COC) as two separate tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP tablet and a COC as two separate tablets
Study: NCT04911062
Drug: Bupivacaine HCI without epinephrine
Normalized name: bupivacaine / epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg administered via injection into the surgical site.
Study: NCT06490601
Drug: thalidomide and hydroxyurea
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity.
Study: NCT05291221
Drug: intratracheal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
Study: NCT04845035
Drug: Berlin-Frankfurt-Münster Chemotherapy
Normalized name: Gila monster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
Study: NCT04845035
Drug: Methotrexate and Cytarabine
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal
Study: NCT05667779
Drug: QRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Study: NCT05097768
Drug: Ketorolac 10 Mg Oral Tablet
Normalized name: ketorolac 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT05097768
Drug: Meloxicam 7.5 mg
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT05097768
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT05097768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT04582305
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
Study: NCT05754684
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone po three time daily
Study: NCT06546423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
Study: NCT05318040
Drug: CMS121
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
Study: NCT04340908
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet, oral, once daily, 1-year treatment, postoperation
Study: NCT05376904
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034 low dose
Study: NCT05376904
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034 midium dose
Study: NCT05376904
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034 high dose
Study: NCT05318040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as visually matching placebo capsules.
Study: NCT06099119
Drug: creon 35.000 Ph.U (R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
Study: NCT06376981
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection of 1 ml of corticosteroids
Study: NCT06376981
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection of 2 ml of placebo (physiological serum)
Study: NCT05837299
Drug: IMC008
Approvals — FDA: no, EMA: no, PMDA: no
Description: allowing 10% dose error
Study: NCT04161599
Drug: Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative for bowel cleansing
Study: NCT04684641
Drug: Standard Dose YPT-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive the standard dose of phage therapy YPT-01.
Study: NCT06244121
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pyridoxine (Vitamin B6) will be given as an anti oxidant.
Study: NCT06244121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in control group
Study: NCT05847322
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
Study: NCT06155578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric cold cream will be applied twice daily on hand calcinosis.
Study: NCT05910892
Drug: Aromatherapy packet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 deep breaths from packet prior to treatment
Study: NCT05910892
Drug: Placebo packet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 deep breaths from packet prior to treatment
Study: NCT03529448
Drug: TN-TC11G
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered.
Study: NCT04749355
Drug: BST-236
Approvals — FDA: no, EMA: no, PMDA: no
Description: BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
Study: NCT04719663
Drug: Active pharmacological placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments.
Study: NCT06024915
Drug: TQ05105 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
Study: NCT04931459
Drug: ACU193
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ACU193
Study: NCT04931459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo
Study: NCT05188131
Drug: Intravenous Infusion of Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
Study: NCT05188131
Drug: Intravenous Infusion of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
Study: NCT04665609
Drug: TQB2450 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
Study: NCT05034536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05419947
Drug: VERDYE powder for solution for injection 25 mg
Normalized name: palo verde pollen extract Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
Study: NCT05147337
Drug: E2511
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E2511 tablets.
Study: NCT05147337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2511 matched placebo tablets.
Study: NCT04707131
Drug: LEM-S401
Approvals — FDA: no, EMA: no, PMDA: no
Description: siRNA encapsulated in DegradaBALL®
Study: NCT04707131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05332678
Drug: SLS-005 - Once Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Arm description.
Study: NCT05332678
Drug: SLS-005 - Twice Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Arm description.
Study: NCT06205641
Drug: Xuanfei Baidu Granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
Study: NCT06205641
Drug: Xuanfei Baidu Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
Study: NCT05471440
Drug: Direct boost mRNA
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA
Study: NCT05471440
Drug: Direct boost adeno
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno
Study: NCT06019065
Drug: AJA001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJA001
Study: NCT05005299
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
Study: NCT04855292
Drug: TG103 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 injection, SC, once weekly
Study: NCT04855292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control, SC, once weekly
Study: NCT05495698
Drug: single-inhaler triple therapy (Trimbow)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
Study: NCT05495698
Drug: multi-inhaler triple therapy (Qvar + Bevespi)
Normalized name: Bevespi Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
Study: NCT05269537
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study: NCT05269537
Drug: Crystalloid Coload 1000 mL
Normalized name: influenza B virus B/Colorado/06/2017 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
Study: NCT06212089
Drug: TR-012001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of TR-012001 will be administered.
Study: NCT05176691
Drug: HMPL-760
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD for 28-day cycles
Study: NCT05167084
Drug: Placebo 250 mg Tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
Study: NCT05355129
Drug: TT-00920 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT04670770
Drug: Drug - SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablets taken once daily for 52 weeks
Study: NCT05068947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT06378697
Drug: Placebo+AK111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
Study: NCT05125081
Drug: Liuwei Dihuang Pill (marketed product in China)
Normalized name: China-Gel Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
Study: NCT00373919
Drug: intravenous (IV) administration of erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05068921
Drug: TQB2858 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Study: NCT05921071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 10 ml of normal saline 0.9% intravenously.
Study: NCT06241196
Drug: Alloderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: allogenic soft tissue substitute
Study: NCT06241196
Drug: Xenogenic bone membrane shield
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: xenogenic bone membrane
Study: NCT05509543
Drug: IY-NT-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10mg
Study: NCT04920747
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel or paclitaxel
Study: NCT04698915
Drug: Drug GC4711
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 Minute IV Infusion
Study: NCT04698915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 Minute IV Infusion
Study: NCT05492968
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study: NCT05749861
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06228820
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
Study: NCT05282251
Drug: Intravenous paracetamol and ketorolac
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo